Media coverage about Cogentix Medical (NASDAQ:CGNT) has trended negative recently, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cogentix Medical earned a news impact score of -0.29 on Accern’s scale. Accern also assigned news coverage about the medical device company an impact score of 46.3243958633899 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Several brokerages have commented on CGNT. Zacks Investment Research cut shares of Cogentix Medical from a “buy” rating to a “hold” rating in a research report on Wednesday, December 20th. Aegis began coverage on shares of Cogentix Medical in a research report on Friday, December 1st. They set a “buy” rating and a $4.75 target price for the company. TheStreet upgraded shares of Cogentix Medical from a “d+” rating to a “c” rating in a research report on Thursday, November 9th. Roth Capital began coverage on shares of Cogentix Medical in a research report on Wednesday, November 8th. They set a “buy” rating and a $4.00 target price for the company. Finally, JMP Securities began coverage on shares of Cogentix Medical in a research report on Friday, October 6th. They set an “outperform” rating and a $5.00 target price for the company. One analyst has rated the stock with a hold rating and three have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $4.06.
Shares of Cogentix Medical (NASDAQ CGNT) traded down $0.08 during trading on Thursday, hitting $2.82. 87,100 shares of the company’s stock traded hands, compared to its average volume of 53,218. The company has a market cap of $176.63, a PE ratio of -6.88 and a beta of 0.66. Cogentix Medical has a 52 week low of $1.55 and a 52 week high of $3.34.
About Cogentix Medical
Cogentix Medical, Inc is a global medical device company. The Company designs, develops, manufactures and markets a line of fiber-optic and video endoscopy products under the PrimeSight brand that are used across various surgical specialties in diagnostic and treatment procedures. The Company also offers the Urgent PC Neuromodulation System (Urgent PC Systems), a device that delivers percutaneous tibial nerve stimulation (PTNS), for the office-based treatment of overactive bladder (OAB).
Receive News & Ratings for Cogentix Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cogentix Medical and related companies with MarketBeat.com's FREE daily email newsletter.